Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Bottom Breakout -- Ignore unavailable to you. Want to Upgrade?

To: Ed Huang who wrote (2461)	5/11/1999 6:49:00 PM
From: froche	Read Replies (1) \| Respond to of 3105

Ed, Thanks, I just jumped in at 1 7/16, 1 17/32 and 1 9/16, looks like I got suckered on the last one... but time will tell. I have heard that some analyst have $3.00 as a target... Thanks for the pointers... Frank

To: Ed Huang who wrote (2461)	5/12/1999 10:05:00 AM
From: Mel Spivak	Read Replies (1) \| Respond to of 3105

PLMD on this earnings report: PolyMedica Announces Record Results FY1999 Revenues Up 42% to $105 Million, Recurring EPS Up 36% to $0.68 Accelerating Shipments Drive Record Fourth Quarter Performance WOBURN, Mass.--(BUSINESS WIRE)--May 12, 1999-- PolyMedica Corporation (Nasdaq: PLMD - news) solidified its position as the No. 1 provider of direct-to-consumer diabetes supplies with record shipments in both the fourth quarter and in fiscal year 1999. Accelerating customer demand created business momentum accompanied by record revenue and earnings for the fiscal fourth quarter and year ended March 31, 1999. For fiscal 1999, net revenues rose 42% to $104.8 million from $73.8 million generated in the prior fiscal year. Pre-tax income from ongoing operations increased 48% to $10.9 million in fiscal 1999. This solid performance reflects the decision by management to launch a marketing program to attract the 2 million Type II diabetics who first became Medicare-eligible for testing supplies on July 1, 1998. Net income from recurring operations increased 36% to $6.7 million, or $0.68 per diluted share, for fiscal 1999, from $4.9 million, or $0.50 per diluted share, for fiscal 1998. The Company generated positive operating cash flow of $539,000 in fiscal 1999, a sharp turnaround from a $9.9 million operating cash outflow in fiscal 1998. Revenue and net income growth, accompanied by positive cash flow, exceeded management's publicly stated targets. The Company shipped to a record number of customers in the fiscal fourth quarter, continuing its pattern of nine consecutive quarters of profitable growth. For the fiscal 1999 fourth quarter, net revenues rose 42% to $30.6 million from $21.6 million in the year earlier. Net income was $2.1 million, or $0.22 per diluted share, compared to $1.5 million, or $0.15 per diluted share, in the same period of the prior fiscal year. ''Clearly we are pleased with our year end and fourth quarter results,'' commented Chairman and CEO Steven J. Lee. ''We are particularly gratified with our across-the-board progress and our strategy of providing consumers with the benefits of home delivery of specialty medical products. Our proprietary database of diabetic seniors in the U.S., specialized customer service systems and a highly trained service force accustomed to assisting seniors with chronic medical conditions are helping to gain growing acceptance in the marketplace. We expect to continue our expansion in diabetes and other related direct-to-consumer categories. ''The Company is enhancing its Web site, developing an interactive disease management system, and increasing its visibility on search engines as part of an effort to explore the potentials of E-commerce. In addition, to support the accelerating growth of our direct-to-consumer business, the Company has purchased a 66,000 square foot facility in St. Lucie county, FL. This facility will be state-of-the-art both in terms of design and technology to further serve the needs of our diabetic customers.'' The company continues to lead its OTC market segment with its popular, high gross margin AZO brand line of female urinary tract discomfort products. In April 1999, PolyMedica began shipments of two new AZO brand products. AZO Menopause(TM) relieves both direct and associated symptoms from hot flashes. There are approximately 30 million women in the menopausal age range of 40-59. AZO Confidence(TM) provides temporary relief of incontinence, which affects approximately 25% of women between the ages of 21 and 64. PolyMedica is best known through its subsidiaries and product lines. The Company's Liberty Medical Supply, Inc. subsidiary is the leading direct mail provider of diabetes testing supplies to seniors who have Medicare coverage. Liberty offers approximately 200 brand-name products from a full range of manufacturers. The Company's AZO line of products has risen to a 47% share of the over-the-counter female urinary tract discomfort market. PolyMedica also is the leading manufacturer and distributor of private-label digital thermometers and has the number two overall market position in thermometers. For more information on PolyMedica, please contact our web site at polymedica.com. This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and ......